| Name | Title | Contact Details |
|---|
Abivax is developing therapies that modulate the body`s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat inflammatory diseases, viral diseases and liver cancer. Abivax is based on innovative research driven by the idea of modulating the body`s natural immune system mechanisms to treat diseases.
Synthorx Inc. is a biotechnology company using synthetic biology to discover and develop novel protein therapeutics. Synthorx`s expanded genetic alphabet platform has the unique ability to drive the site-specific incorporation of multiple synthetic amino acids into proteins thereby tuning receptor specificity important for improving efficacy and safety. In addition, their engineered organisms provide the ability to manufacture these improved proteins, called Synthorins, with the required fidelity and yield. The unique Synthorx platform expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics, not possible with other technologies. The company was founded based on important discoveries in Dr. Floyd Romesberg`s lab at The Scripps Research Institute in conjunction with Avalon Ventures, which housed Synthorx in its incubator, COI Pharmaceuticals, Inc. The company is headquartered in La Jolla, Calif.
Celator Pharmaceuticals is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr Virus, and will pursue opportunities to address other serious virus-associated disease.
Zymo Research Corporation is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.